Earnings Presentation for the quarter ended June 30, 2026

July 31, 2026 National Stock Exchange of India Limited BSE Limited Exchange Plaza, Bandra-Kurla Complex, Phiroze Jeejeebhoy Towers, Bandra (E), Mumbai - 400 051, Maharashtra. Dalal Street, Mumbai – 400 001, Maharashtra. Symbol: STAR Scrip Code: 532531 Dear Madam/ Sir, Sub: Earnings Presentation for the quarter ended June 30, 2026 Ref: Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 (“SEBI Listing Regulations”) We are pleased to enclose the Earnings Presentation for Q1 FY27 dated July 31, 2026. The Board Meeting for considering the unaudited financial results for the quarter ended June 30, 2026 commenced at 10:30 hrs IST and concluded at 12:30 hrs IST. The above information shall be made available on the website of the Company at www.strides.com. This is for your information and records. Thanks & Regards, For Strides Pharma Science Limited, Manjula Ramamurthy Company Secretary & Compliance Officer ICSI Membership No.: A30515 Encl. as above Strides Pharma Science Limited CIN: L24230MH1990PLC057062 Corp. Off: Strides House, Bilekahalli, Bannerghatta Road, Bengaluru – 560 076, India |Tel: +91 80 6784 0000 Regd. Off: ‘Cyber One’, Unit No. 902, Plot No. 4&6, Sector 30A, Vashi, Navi Mumbai – 400 703, India | Tel: +91 22 2789 2924/3199 corpcomm@strides.com; www.strides.com Q1FY27 Earnings Presentation July 31, 2026 Strides Pharma Science Limited Health where it matters Safe Harbor Except for the historical information contained herein, statements in this presentation and the subsequent discussions, which include words or phrases such as "will", "aim", "will likely result", "would", "believe", "may", "expect", "will continue", "anticipate", "estimate", "intend", "plan", "contemplate", “seek to", "future", "objective", "goal", "likely", "project", "should", "potential", "will pursue", and similar expressions of such expressions may constitute "forward-looking statements“. These forward-looking statements involve a number of risks, uncertainties, and other factors that could cause actual results to differ materially from those suggested by the forward-looking statements. These risks and uncertainties include, but are not limited to our ability to successfully implement our strategy, our growth and expansion plans, obtain regulatory approvals, our provisioning policies, technological changes, investment and business income, cash flow projections, our exposure to market risks as well as other risks. The Company does not undertake any obligation to update forward-looking statements to reflect events or circumstances after the date thereof. Health where it matters 2 Strides Delivers Steady Performance with Revenue at ₹12,654m, Grew 13% YoY; Ex-US Markets Grew 17% YoY EBITDA Grew 5.4% YoY to ₹2,298m, Despite a ~₹131m Impact on Freight and Operating Costs from Geopolitical Disruptions; Operational PAT at ₹1,231m with Operational EPS at ₹13.4; Reported PAT at ₹1,655m with Reported EPS at ₹17.0 Q1FY27 Q1FY26 YoY Change Strides delivered a steady start to FY27 with revenue growth of 13% YoY. Our investments in Ex-US Markets over the past few years are now yielding strong results, delivering 17% YoY Revenue (₹m) 12,654 11,197 13.Y0o%Y  growth and reinforcing the strength of our diversified business strategy. Our focus on execution and operating discipline enabled us to Gross Margins (₹m) 7,702 6,755 14.0%  grow absolute gross margins by 14% YoY. EBITDA grew ~5% YoY to ₹2,298m, despite ~₹131m impact Gross Margin (%) 60.9% 60.3% 60bps  from elevated operating and freight cost arising from the ongoing geopolitical situation. We remain focused on mitigating these pressures through continuous cost EBITDA (₹m) 2,298 2,181 5.4%  optimization initiatives. We reduced net debt by ₹119m, with Net Debt-to-EBITDA at 1.52x, despite significant working capital investments required EBITDA Margin (%) 18.2% 19.5% -130bps to navigate the current business environment and growth. During the quarter, we unlocked ₹1,000m of value through the divestment of our majority stake in Pivot Path, our captive Operational PAT (₹m) 1,231 1,140 8.0%  GCC, while retaining meaningful participation in its future growth. We also improved our EcoVadis sustainability score to 68/100, Operational EPS (₹) 13.4 12.4 8.0%  a 19-point increase over last year. While the external environment remains dynamic, we remain focused on delivering sustainable and profitable growth. Reported PAT (₹m) 1,655 1,056 56.7%  Badree Komandur MD and Group CEO Reported PAT includes gain on sale of majority stake in Pivot Path, Strides captive GCC Operational PAT = Reported PAT excluding exceptional items Health where it matters 3 Sustained YoY Growth Across P&L Metrics Profitability Focus Combined with Growth in Ex-US Markets Delivered an Operating EPS of ₹13.4 Total Revenue (₹M) Gross Margin (₹M) EBITDA (₹M) Operational PAT (₹M) Gross Margin Gross Margin (%) EBITDA EBITDA (%) 19.8% 8,500 70.0% 2,500 19.5% 20.0% 19.0% 61.2% 59.5% 60.9% 8,000 60.3% 57.8% 2,400 18.1% 18.2% 19.0% 0 4 3 0 2 8 9 5 1 3 60.0% 1 4 2 3 2 ,1 ,1 ,1 ,1 ,1 7,500 2,300 18.0% 50.0% 2,200 17.0% Q1FY26 Q2FY26 Q3FY26 Q4FY26 Q1FY27 7,000 2,100 16.0% 40.0% Operational EPS (₹) 6,500 2,000 15.0% 6,000 30.0% 1,900 14.0% 5,500 1,800 13.0% 20.0% 5,000 7 8 6 5 4 1,700 12.0% 9 1 ,1 1 0 2 ,2 1 4 9 ,1 1 3 2 ,3 1 5 6 ,2 1 4,500 5 5 7 ,6 6 5 0 ,7 7 1 3 ,7 2 7 8 ,7 2 0 7 ,7 10.0% 1,600 1 8 1 ,2 6 1 3 ,2 9 5 3 ,2 7 9 3 ,2 8 9 2 ,2 11.0% 4 .2 2 .5 9 .3 7 .4 4 .3 4,000 0.0% 1,500 10.0% Q1FY26 Q2FY26 Q3FY26 Q4FY26 Q1FY27 Q1FY26 Q2FY26 Q3FY26 Q4FY26 Q1FY27 Q1FY26 Q2FY26 Q3FY26 Q4FY26 Q1FY27 Q1FY26 Q2FY26 Q3FY26 Q4FY26 Q1FY27 • Strong YoY growth recorded across • Consistent YoY growth in absolute • YoY Growth in absolute EBITDA • EBITDA to PAT conversion at ~50%+ Ex-US Markets gross margin • EBITDA Margin continues to be impacted by external headwinds • Margins profile to remain steady in ~58% to 60% Health where it matters 4 Ex-US Markets Continue to Deliver Strong 17% YoY Growth Revenue Composition (₹M) US Market (₹M) Ex-US Markets (₹M) Access Market* (₹M) Access Market Ex-US US 4%  17%  100%+  54% 50% 6 3 2 8 7 1 5 7 ₹ 7 0 2 0 8 9 ,6 ,6 ,5 ,5 4 1% 4% ₹ ₹ ₹ ₹ ₹ Q1FY26 Q1FY27 Q1FY26 Q1FY27 Q1FY26 Q1FY27 Q1FY26 Q1FY27 *Tactical Business Health where it matters 5 US Market Health where it matters Q1FY27 Revenue Remains Steady at ₹6,282m ($68m), H2 Expected to be Stronger with New Launches Year-on-Year Comparison (₹/$M) Comments • Q1FY27 revenue at $68m, remained steady despite new entrants in recent launches YoY 4% • Launched 2 products in Q1FY27 • Total number of commercialized products stood at 72 ₹ 6,036 ₹ 6,282 • Slower than expected quota allocation is impacting Controlled Substances revenue growth • New product approvals are expected in H2FY27 • Continue to rank amongst the top 3 in 37 products, enjoying a market-leading position, $71 $68 contributing ~70% of our total US revenue Q1FY26 Q1FY27 Quarterly Trend (₹/$M) Business Outlook Generics ₹ 6,467 • Aspire to focus on North America Business Revenue of ~$375m by FY28 despite current ₹ 6,289 ₹ 6,282 ₹ 6,036 ₹ 6,105 external headwinds • Multiple products have been identified from our dormant and acquired ANDAs portfolio, which are under various regulatory phases of PAS (prior approvals supplements) for source change and cost leadership to be relaunched to achieve the stated aspiration • 228 ANDAs filed, 210 ANDAs approved (152 products) as of Jun’26 New Updates • Investing in building a portfolio of Control Substances, Nasal Sprays, Transdermal $71 $73 $70 $70 $68 Patches and Films as part of a long-term strategy • Filed Second Nasal Spray product (Controlled substance) in May’26 Q1FY26 Q2FY26 Q3FY26 Q4FY26 Q1FY27 • Continuing to build on these domains with additional filings and approvals expected in YoY growth are on ₹ reported numbers the near term. Health where it matters 7 Ex-US Markets Health where it matters Ex-US Markets Revenue at ₹5,875m ($63m), Grew 17% YoY, Dri [Showing first 8,000 characters — download PDF for full document]